BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ for NOVO NORDISK, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICOLE CARELLI New | — |
| CAROLINE SELBY New | — |
| TIFFANI VIVIENNE WILLIAMS New | — |
Medicare/Medicaid MMM
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICOLE CARELLI New | — |
| CAROLINE SELBY New | — |
| TIFFANI VIVIENNE WILLIAMS New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| NOVO NORDISK FONDEN (FOUNDATION) | Denmark | Denmark | 25.0% | — |
| NOVO NORDISK A/S | Denmark | Denmark | 100.0% | — |
| NOVO A/S | Denmark | Denmark | 25.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.